In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allos Therapeutics Inc.

Division of Spectrum Pharmaceuticals Inc.

Latest From Allos Therapeutics Inc.

Appointments: Sanofi, Fosun Kite, Milestone, Tocagen, GW Pharma, Hookipa and Bone Therapeutics

This week’s round-up includes the appointment of independent directors by Sanofi’s board of directors, CEO appointments by Fosun Kite Biotechnology and Milestone Pharmaceuticals as well as executive appointments by Tocagen, GW Pharmaceuticals, Bone Therapeutics and Tris Pharma.

Appointments BioPharmaceutical

INTERVIEW: Chipscreen CEO Bets Big On Chinese Innovation

When initial funding burned through and co-founders bailed out, Chipscreen CEO Lu Xianping faced the biggest challenge of his career. A firm belief in scientific evidence and an unwavering confidence in China-originated innovation helped him launch chidamide, a true made in China drug for a rare blood cancer, Lu told PharmAsia News in an exclusive interview.

BioPharmaceutical China

China FDA Set To Greenlight First Domestic Lymphoma Drug

On the verge of obtaining its first new drug approval from the China FDA to treat a rare cancer type, Chinese domestic biotech ChipScreen is poised to benefit from an increasingly confident regulatory agency.

BioPharmaceutical China

Anacor names Paul Berns president and CEO

Anacor, a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics, has named Paul Berns – currently chair of the board – president and CEO effective immediately. Mr Berns succeeds David P Perry who was Anacor's president and CEO from 2002. Mr Berns most recently served as president and CEO of Allos Therapeutics before that company's acquisition by Spectrum Pharmaceuticals in 2012.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Spectrum Pharmaceuticals Inc.
  • Senior Management
  • Paul L Berns, Pres. & CEO
    David C Clark, VP, Fin.
    Michael E Schick, VP, Sales & Mktg.
  • Contact Info
  • Allos Therapeutics Inc.
    Phone: (303) 426-6262
    11080 CirclePoint Rd.
    Ste. 200
    Westminster, CO 80020